Test and Treat Sparks New Healthcare Debate

AMA raises concern about pharmacists providing antiviral therapy.

In President Joe Biden’s State of the Union address, he announced the launch of a Test and Treat Initiative, where consumers testing positive for COVID-19 at certain pharmacies will be given antiviral therapy by an on-site provider on the spot and at no cost

However, there’s already a debate about who should be able to prescribe these antiviral pills as the U.S. Department of Health and Human Services (HHS) began distributing them in the last few weeks.

The American Medical Association (AMA) expressed concern about the initiative allowing a provider without an established patient-doctor relationship with the consumer to prescribe the pills.  In other words, the AMA is uncomfortable with pharmacists or anyone else without an ongoing and well-established medical relationship with the patient prescribing anything under the initiative.  According to the AMA, one of the antivirals to be prescribed has over six pages of drug interactions that would require patients to modify or even stop other prescriptions they are taking.  The organization stated that prescribing these without full patient history and ongoing monitoring sets a very dangerous precedent because while these pharmacy-based clinics are equipped to treat simple conditions, COVID-19 and the antiviral medications that treat it are too complicated for this on-site service.

On the flip side, pharmacists believe they should be able to prescribe the antivirals if the initiative hopes to meet its stated goal of providing the most vulnerable and underserved Americans with access to lifesaving treatment.  Pharmacists believe that expanding the power to prescribe these pills beyond just on-site providers would not only expand access to the initiative but also would be an obvious and safe choice considering pharmacists’ extensive knowledge of medication and side effects. 

When asked about the reach of the initiative, pharmacists say that not only should the program be expanded to include a lot more pharmacies nationwide, but that the best way to do that would be to allow them to prescribe the antiviral pills. However, currently the Test and Treat initiative limits participating pharmacies to just those with onsite clinics with a provider.

These types of pharmacies are far less likely to be found in rural and sparsely populated areas.  For example, CVS Minute Clinics, which would be eligible to prescribe antivirals under the initiative, make up only 10 percent of all CVS Pharmacies. By limiting the ability to prescribe the antiviral pills to these pharmacies with on-site providers, thousands of other pharmacies across America are ineligible to participate, many in areas that serve some of the hardest hit populations and populations without insurance.   

Additionally, pharmacists also believe they would be the perfect prescribers of the antiviral pills.  In fact, they say they have already been prescribing some COVID treatments since last year under other federal statutes. Pharmacists also have extensive knowledge about medication, of course, and understand potential interactions and side effects.  When asked about the issue, one professor of pharmacy even called pharmacists “medication experts”.

After the AMA issued a statement about their concerns, the Biden administration encouraged people who do have a regular health care provider to continue seeing that provider for testing or when they’ve received a positive COVID-19 test at a treatment site.  This appears to have pacified the AMA and other physicians’ worries for the time being. However, there is still a very real concern for Americans without insurance and without access to a primary care physician.

As antiviral pills have begun arriving at pharmacies that signed up for the initiative, a federal website to search and find locations has yet to fully launch but is expected by months end. 

With COVID-19 cases falling, increased vaccine and testing availability, and now increased treatment options, Americans are rapidly moving towards a new normal as we hit the two-year anniversary of COVID-19 lockdowns.

Facebook
Twitter
LinkedIn

Cate Brantley, JD

Cate Brantley is a Senior Government Affairs Liaison for Zelis. She has over 9 years of experience in both the public and private sector. Cate is licensed to practice law in the state of Oklahoma.

Related Stories

Leave a Reply

Please log in to your account to comment on this article.

Featured Webcasts

2026 IPPS Masterclass 3: Master MS-DRG Shifts and NTAPs

2026 IPPS Masterclass Day 3: MS-DRG Shifts and NTAPs

This third session in our 2026 IPPS Masterclass will feature a review of FY26 changes to the MS-DRG methodology and new technology add-on payments (NTAPs), presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 14, 2025
2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

2026 IPPS Masterclass Day 2: Master ICD-10-PCS Changes

This second session in our 2026 IPPS Masterclass will feature a review the FY26 changes to ICD-10-PCS codes. This information will be presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 13, 2025
2026 IPPS Masterclass 1: Master ICD-10-CM Changes

2026 IPPS Masterclass Day 1: Master ICD-10-CM Changes

This first session in our 2026 IPPS Masterclass will feature an in-depth explanation of FY26 changes to ICD-10-CM codes and guidelines, CCs/MCCs, and revisions to the MCE, presented by presented by nationally recognized ICD-10 coding expert Christine Geiger, MA, RHIA, CCS, CRC, with bonus insights and analysis from Dr. James Kennedy.

August 12, 2025

Trending News

Featured Webcasts

The Two-Midnight Rule: New Challenges, Proven Strategies

The Two-Midnight Rule: New Challenges, Proven Strategies

RACmonitor is proud to welcome back Dr. Ronald Hirsch, one of his most requested webcasts. In this highly anticipated session, Dr. Hirsch will break down the complex Two Midnight Rule Medicare regulations, translating them into clear, actionable guidance. He’ll walk you through the basics of the rule, offer expert interpretation, and apply the rule to real-world clinical scenarios—so you leave with greater clarity, confidence, and the tools to ensure compliance.

June 19, 2025
Open Door Forum Webcast Series

Open Door Forum Webcast Series

Bring your questions and join the conversation during this open forum series, live every Wednesday at 10 a.m. EST from June 11–July 30. Hosted by Chuck Buck, these fast-paced 30-minute sessions connect you directly with top healthcare experts tackling today’s most urgent compliance and policy issues.

June 11, 2025
Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Open Door Forum: The Changing Face of Addiction: Coding, Compliance & Care

Substance abuse is everywhere. It’s a complicated diagnosis with wide-ranging implications well beyond acute care. The face of addiction continues to change so it’s important to remember not just the addict but the spectrum of extended victims and the other social determinants and legal ramifications. Join John K. Hall, MD, JD, MBA, FCLM, FRCPC, for a critical Q&A on navigating substance abuse in 2025.  Register today and be a part of the conversation!

July 16, 2025

Trending News

Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →

CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24